Document Detail


Development and characterization of acellular allogeneic arterial matrices.
MedLine Citation:
PMID:  21919791     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Surgeons have used cryopreserved vascular allografts successfully for many years to treat arterial occlusive disease and to repair arterial aneurysms. Vascular allografts demonstrate high patency rates but contain viable cells, which may evoke a rejection response following implantation. Removing the cells could prevent such a response and negate the need for cryopreservation and ultra-low temperature storage. The objectives of the study were to characterize human common femoral arteries and develop a decellularization protocol with a view to the generation of biocompatible and biomechanically functional vascular grafts for use in vascular bypass and arteriovenous access. The arteries were decellularized by subjecting the tissue to a single freeze-thaw cycle followed by sequential incubation in hypotonic tris buffer and low concentration sodium dodecyl sulphate. Each artery was disinfected using 0.1% (v/v) peracetic acid. Histological analysis demonstrated a lack of cells following decellularization and confirmed the integrity of the tissue histioarchitecture and retention of major structural proteins. There was a >95% reduction in DNA levels. The acellular tissues and extracts were not cytotoxic to either mouse 3T3 or baby hamster kidney cells. Biomechanical properties were determined by burst pressure, compliance, and tensile tests, which confirmed the retention of biomechanical properties following decellularization. In conclusion the study has developed a suitable protocol for the removal of cells from human common femoral arteries without adversely affecting the biochemical or biomechanical properties. These properties indicate the potential use for acellular human common femoral arteries for vascular bypass or arteriovenous access.
Authors:
Stacy-Paul Wilshaw; Paul Rooney; Helen Berry; John N Kearney; Shervanthi Homer-Vanniasinkam; John Fisher; Eileen Ingham
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't     Date:  2011-11-02
Journal Detail:
Title:  Tissue engineering. Part A     Volume:  18     ISSN:  1937-335X     ISO Abbreviation:  Tissue Eng Part A     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-03-01     Completed Date:  2012-06-18     Revised Date:  2014-03-19    
Medline Journal Info:
Nlm Unique ID:  101466659     Medline TA:  Tissue Eng Part A     Country:  United States    
Other Details:
Languages:  eng     Pagination:  471-83     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
3T3 Cells
Animals
Arterial Occlusive Diseases / surgery
Bioprosthesis*
Blood Vessel Prosthesis*
Cricetinae
Female
Femoral Artery / chemistry*,  transplantation
Humans
Male
Materials Testing / methods*
Mice
Organ Transplantation
Transplantation, Homologous
Grant Support
ID/Acronym/Agency:
HTD 430//Department of Health; WT088908/Z/09/Z//Wellcome Trust; //Department of Health

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Intervertebral disk tissue engineering using biphasic silk composite scaffolds.
Next Document:  Oxygen tension and formation of cervical-like tissue in two-dimensional and three-dimensional cultur...